Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
In the overall trial population, survival results numerically favored Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan…